Purpose
- Buccal delivery allows bypassing first-pass metabolism
- Evaluating buccal mucosal permeability is necessary to assess the pharmacokinetics (PK) of active pharmaceutical ingredients (APIs) intraorally delivered using mechanistic in silico approaches
- In vitro permeability assays were conducted using the organotypic EpiOral™ tissue model (ORL-200, MatTek Corp., Ashland, MA) (cf. Poster #T1030-04-26)
- A mechanistic in silico model of the EpiOral™ tissue was developed and validated in MembranePlus™ software (beta version, Simulations Plus Inc., Lancaster, CA)
- Diffusivity (Dm) and fraction unbound (fut) in the oral mucosa of the EpiOral™ tissue were determined for 8 APIs.
By Priyata Kalra, Maxime Le Merdy, Viera Lukacova, Pankaj Dwivedi, Khondoker Alam, Eleftheria Tsakalozou, Manar Al-Ghabeish, Giovanni Pauletti2, Haiying Zhou
AAPS 2023 PharmSci 360,Orlando, FL, October 22-25, 2023